<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03091504</url>
  </required_header>
  <id_info>
    <org_study_id>BDTHFNC01</org_study_id>
    <nct_id>NCT03091504</nct_id>
  </id_info>
  <brief_title>Evaluation on the Efficacy of Bronchodilator Nebulization Via High Flow Nasal Cannula</brief_title>
  <official_title>Evaluation on the Efficacy of Bronchodilator Nebulization Via High Flow Nasal Cannula</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>People's Hospital of Xinjiang Uygur Autonomous Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      High-humidity nasal cannula (HFNC) has been shown to be effective in improving oxygenation
      and avoiding intubation in multiple randomized control trials, it is also suitable and
      feasible for long term use. Aerosol delivery via HFNC will minimize interruptions and improve
      patient compliance, bench study and radionuclide imaging study done in healthy volunteers
      demonstrated that aerosol can be effectively delivered using HFNC. This study aims to
      evaluate the efficacy of bronchodilator delivered via HFNC in chronic pulmonary obstructive
      disease or asthma patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic obstructive pulmonary disease or asthma patients who have positive response in
      bronchodilator test will be consented and enrolled, patients come back for the second
      bronchodilator assessment within one to three days after the initial bronchodilator test.
      Albuterol with different concentration will be provided to the patients via HFNC, patients
      will be assessed by spirometry after each concentration until bronchodilator response is
      positive and does not improve after the next dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 4, 2017</start_date>
  <completion_date type="Actual">March 31, 2018</completion_date>
  <primary_completion_date type="Actual">March 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 change from initial</measure>
    <time_frame>30-60 mins</time_frame>
    <description>FEV1 abs Δ: post FEV 1 - pre FEV1 and FEV1 %Δinit: (post FEV1 - pre FEV1)/pre FEV1 × 100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Breath sound</measure>
    <time_frame>30-60 mins</time_frame>
    <description>Wheezing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>30-60 mins</time_frame>
    <description>The number of heart beats per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>30-60 mins</time_frame>
    <description>About 4,630,000 results (0.68 seconds)
Search Results
The number of breaths per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>30-60 mins</time_frame>
    <description>Tremor</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>High Flow Nasal Cannula</condition>
  <arm_group>
    <arm_group_label>Albuterol via High flow nasal cannula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled patients inhale bronchodilator (Albuterol Sulfate) with different concentration via High flow nasal cannula, prepared albuterol concentrations are 0.5mg, 1.0mg, 2.0mg and 4.0mg, patients will be assessed by spirometry after each concentration until bronchodilator response is positive and does not improve after the next dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High flow nasal cannula</intervention_name>
    <description>High flow nasal cannula is a soft and flexible nasal prongs with adjustable head strap fits over the patient's ears, it delivers a broad variety of gas flows directly into the nares without gas jetting.</description>
    <arm_group_label>Albuterol via High flow nasal cannula</arm_group_label>
    <other_name>Optiflow, Fisher Paykel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albuterol Sulfate</intervention_name>
    <description>Albuterol is a short acting inhaled bronchodilator</description>
    <arm_group_label>Albuterol via High flow nasal cannula</arm_group_label>
    <other_name>Ventolin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnose with COPD or asthma

          -  Bronchodilator test is positive (According to ATS guidelines, FEV1 change from initial
             more than 12% and FEV1 absolute change more than 200 mL);

          -  Age &gt; 18yrs and &lt; 90yrs

        Exclusion Criteria:

          -  Recent pulmonary exacerbation

          -  Mental disease

          -  Uncooperative

          -  Reluctant to participate

          -  Patients who are unable to come back to get the second spirometry within three days

          -  Contraindicated to Albuterol (Ventolin, GSK)

               -  Rest HR &gt; 100 beats/min

               -  Serum K+ &lt; 2.8 mmol/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minghua Zhao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>People's Hospital of Xinjiang Uygur Autonomous Region</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>People's Hospital of Xinjiang Uygur Autonomous Region</name>
      <address>
        <city>Ürümqi</city>
        <state>Xinjiang</state>
        <zip>830001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Dailey PA, Harwood R, Walsh K, Fink JB, Thayer T, Gagnon G, Ari A. Aerosol Delivery Through Adult High Flow Nasal Cannula With Heliox and Oxygen. Respir Care. 2017 Sep;62(9):1186-1192. doi: 10.4187/respcare.05127. Epub 2017 Jun 6.</citation>
    <PMID>28588117</PMID>
  </reference>
  <reference>
    <citation>Réminiac F, Vecellio L, Heuzé-Vourc'h N, Petitcollin A, Respaud R, Cabrera M, Pennec DL, Diot P, Ehrmann S. Aerosol Therapy in Adults Receiving High Flow Nasal Cannula Oxygen Therapy. J Aerosol Med Pulm Drug Deliv. 2016 Apr;29(2):134-41. doi: 10.1089/jamp.2015.1219. Epub 2015 Jul 21.</citation>
    <PMID>26196740</PMID>
  </reference>
  <reference>
    <citation>Dugernier J, Hesse M, Jumetz T, Bialais E, Roeseler J, Depoortere V, Michotte JB, Wittebole X, Ehrmann S, Laterre PF, Jamar F, Reychler G. Aerosol Delivery with Two Nebulizers Through High-Flow Nasal Cannula: A Randomized Cross-Over Single-Photon Emission Computed Tomography-Computed Tomography Study. J Aerosol Med Pulm Drug Deliv. 2017 Oct;30(5):349-358. doi: 10.1089/jamp.2017.1366. Epub 2017 May 2.</citation>
    <PMID>28463044</PMID>
  </reference>
  <reference>
    <citation>Réminiac F, Vecellio L, Loughlin RM, Le Pennec D, Cabrera M, Vourc'h NH, Fink JB, Ehrmann S. Nasal high flow nebulization in infants and toddlers: An in vitro and in vivo scintigraphic study. Pediatr Pulmonol. 2017 Mar;52(3):337-344. doi: 10.1002/ppul.23509. Epub 2016 Jul 8.</citation>
    <PMID>27392199</PMID>
  </reference>
  <reference>
    <citation>Morgan SE, Mosakowski S, Solano P, Hall JB, Tung A. High-Flow Nasal Cannula and Aerosolized β Agonists for Rescue Therapy in Children With Bronchiolitis: A Case Series. Respir Care. 2015 Sep;60(9):e161-5. doi: 10.4187/respcare.03996. Epub 2015 Jun 23.</citation>
    <PMID>26106204</PMID>
  </reference>
  <reference>
    <citation>Baudin F, Buisson A, Vanel B, Massenavette B, Pouyau R, Javouhey E. Nasal high flow in management of children with status asthmaticus: a retrospective observational study. Ann Intensive Care. 2017 Dec;7(1):55. doi: 10.1186/s13613-017-0278-1. Epub 2017 May 22.</citation>
    <PMID>28534235</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rush University Medical Center</investigator_affiliation>
    <investigator_full_name>Jie Li</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Bronchodilator Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

